Ashley Dombkowski had global responsibility for 23andMe’s translational collaboration initiatives. She was previously a member of the Board of Directors at 23andMe and was a Managing Director at MPM Capital. She currently is the Managing Director with Bay City Capital. During her years as a healthcare venture capitalist she focused on developing innovative, entrepreneurial biotechnology and medical device companies, including companies such as Alnara, BioVitrum, Epizyme, Hemosense, iPierian, Neosil, Nevro, Rigel, and Tercica. Prior to this position, she was a Healthcare Equity Analyst for Tiger Management and for Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in Mathematics from Rice University for her work in partial differential equations and geometric measure theory. She received her B.A. in mathematics from Wellesley College where she was inducted into the Sigma Xi Scientific Research Society, and was awarded The Lewis Atterbury Stimson Prize in Mathematics. A member of the Wellesley College Business Leadership Council, she was recognized as one of the 100 Most Influential Women in Business by the San Jose/Silicon Valley Business Journal in 2010.